ClinicalTrials.gg
CompletedNCT02115347Updated Aug 20, 2018Results posted

Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)

A Phase 1 interventional study of Ertugliflozin 15 mg in Type 2 Diabetes Mellitus and Hepatic Impairment, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-20.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.

Enrollment
25th of 28
16 · median 83
Started
2014
with 3 others
Phase 1
8 of 28
none open now
Registered
15th of 28
by date
Lead sponsor
18 of 28
Merck Sharp & Dohme LLC

Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 25th largest by enrollment, is one of 4 that started in 2014, is one of 8 in phase 1, and was the 15th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ertugliflozin

ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a study to assess the pharmacokinetics and safety of ertugliflozin (MK-8835, PF-04971729) in participants with hepatic impairment versus healthy participants. In Part 1 of the study, participants with moderate hepatic impairment (Child-Pugh score 7-9) and matched healthy participants will be enrolled; depending on results in Part 1, Part 2 may be conducted and will enroll participants with mild hepatic impairment (Child-Pugh score 5-6).

03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Hepatic Impairment
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

ALL PARTICIPANTS:

  • (BMI) of 18 to 40 kg/m\^2; and a total body weight >50 kg (110 lbs)
  • Male or female not of
  • If a female of reproductive potential, agrees to remain abstinent from heterosexual activity or agree to use or have their partner use 2 methods of acceptable to prevent pregnancy while the participant is receiving study medication and for 14 days after the last dose of study medication PARTICIPANTS WITH NORMAL HEPATIC FUNCTION
  • Healthy with normal hepatic function PARTICIPANTS WITH HEPATIC IMPAIRMENT
  • Satisfy the criteria for classification [moderate (Part 1): Child-Pugh Scores 7-9 points, mild (Part 2): Child-Pugh Scores 5-6 points] within 14 days before administration of study medication
  • A diagnosis of hepatic impairment due to primary liver disease and not secondary to other diseases
  • Stable hepatic impairment, defined as no clinically-significant change in disease status within the last 30 days
  • On a stable dose of medication and/or treatment regimen used to manage hepatic disease for at least 4 weeks prior to study start

Exclusion criteria

Exclusion Criteria:

ALL PARTICIPANTS

  • A known or intolerance to ertugliflozin or any other Sodium-Glucose co-Transporter 2 (SGLT2) inhibitor (i.e., canagliflozin [Invokana], dapagliflozin [Farxiga], empagliflozin, or ipragliflozin)
  • Febrile illness within 5 days prior to the first dose of study medication
  • Any malabsorption condition
  • A positive urine drug screen for drugs of abuse or recreational drugs
  • Abuse of alcohol or binge drinking and/or any other illicit drug use or dependence within 6 months of study start
  • Treatment with an drug within 30 days preceding the first dose of study medication
  • Pregnant or breastfeeding females
  • Use of herbal supplements within 28 days prior to the first dose of study medication
  • Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing
  • History of sensitivity to heparin or heparin-induced thrombocytopenia PARTICIPANTS WITH NORMAL HEPATIC FUNCTION
  • Use of prescription drugs (hormonal methods of are allowed), vitamins, and dietary supplements within 7 days prior to the first dose of study medication
  • Positive serology for or C PARTICIPANTS WITH HEPATIC IMPAIRMENT
  • Hepatic carcinoma and hepatorenal syndrome or less than 1 year
  • Undergone portal-caval shunt surgery
  • History of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers less than 1 month prior to study entry
  • Signs of significant hepatic encephalopathy
  • Severe ascites and/or pleural effusion
  • A transplanted kidney, heart or liver
  • Received any of the following medications within 7 days prior to the first dose of study medication or during the study: other SGLT2 inhibitors (eg, dapagliflozin, canagliflozin, empagliflozin, and ipragliflozin); any potent drug-metabolizing enzyme-inducing drug, including rifampin, phenytoin, and carbamazepine; probenecid, valproic acid, gemfibrozil
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Ertugliflozin 15 mg - Moderate Hepatic Impairment

    Participants receive a single 15 mg oral dose (tablet) of ertugliflozin

    Drug: Ertugliflozin 15 mg

  • Other
    Ertugliflozin 15 mg - Healthy Participants

    Participants receive a single 15 mg oral dose (tablet) of ertugliflozin

    Drug: Ertugliflozin 15 mg

  • Experimental
    Ertugliflozin 15 mg - Mild Hepatic Impairment

    Participants receive a single 15 mg oral dose (tablet) of ertugliflozin

    Drug: Ertugliflozin 15 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin

    Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration (AUClast).

    Time frame: Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours

  2. AUC From Hour 0 to Infinity (AUCinf) for Ertugliflozin

    Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf).

    Time frame: Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours

Secondary outcomes

  1. AUClast for Fraction of Ertugliflozin Unbound in Plasma (AUClast,u)

    Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration (Clast) for unbound drug (ertugliflozin only).

    Time frame: Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours

  2. AUCinf for Fraction of Ertugliflozin Unbound in Plasma (AUCinf,u)

    Area under the plasma concentration-time profile from time zero extrapolated to infinite time for unbound drug (ertugliflozin only) (AUCinf, u).

    Time frame: Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours

  3. Maximum Plasma Concentration (Cmax) of Ertugliflozin

    Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.

    Time frame: Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours

  4. Cmax for Fraction of Ertugliflozin Unbound in Plasma (Cmax,u)

    Maximum plasma concentration for unbound drug (ertugliflozin only).

    Time frame: Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours

  5. Number of Participants Who Experienced an Adverse Event

    An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 19 days

07

Results

Posted Aug 3, 2018

Participant flow

Based on a statistical evaluation of the pharmacokinetic (PK) data obtained from participants with moderate hepatic impairment and matched healthy volunteers, and the pre-specified decision criteria, Part 2 of the study was not conducted and participants with mild hepatic impairment were not enrolled.

Participant flow — Overall Study
MilestoneErtugliflozin 15 mg (Moderate Hepatic Impairment)Ertugliflozin 15 mg (Normal Hepatic Function)Ertugliflozin 15 mg - Mild Hepatic Impairment
Started880
Completed880
Not completed000

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin

Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration (AUClast).

Time frame:
Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours
Reported as:
Geometric mean · ng•hr/mL
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin
ng•hr/mLErtugliflozin 15 mg (Moderate Hepatic Impairment)Ertugliflozin 15 mg (Normal Hepatic Function)
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin1413 ± 391618 ± 14
Statistical analysis
  • Ertugliflozin 15 mg (Moderate Hepatic Impairment) vs Ertugliflozin 15 mg (Normal Hepatic Function) · Ratio (test/reference) of adjusted means: 87.31 · 90% CI 68.01 to 112.08ANOVA model with hepatic function group as a fixed effect, ratios (and 90% confidence intervals \[CIs\]) were expressed as percentages, Moderate Hepatic Impairment (Test), Normal Hepatic Function (Reference).
PrimaryAUC From Hour 0 to Infinity (AUCinf) for Ertugliflozin

Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf).

Time frame:
Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours
Reported as:
Geometric mean · ng•hr/mL
AUC From Hour 0 to Infinity (AUCinf) for Ertugliflozin
ng•hr/mLErtugliflozin 15 mg (Moderate Hepatic Impairment)Ertugliflozin 15 mg (Normal Hepatic Function)
AUC From Hour 0 to Infinity (AUCinf) for Ertugliflozin1430 ± 391636 ± 14
Statistical analysis
  • Ertugliflozin 15 mg (Moderate Hepatic Impairment) vs Ertugliflozin 15 mg (Normal Hepatic Function) · Ratio (test/reference) of adjusted means: 87.43 · 90% CI 68.11 to 112.22ANOVA model with hepatic function group as a fixed effect, ratios (and 90% confidence intervals \[CIs\]) were expressed as percentages, Moderate Hepatic Impairment (Test), Normal Hepatic Function (Reference).
SecondaryAUClast for Fraction of Ertugliflozin Unbound in Plasma (AUClast,u)

Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration (Clast) for unbound drug (ertugliflozin only).

Time frame:
Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours
Reported as:
Geometric mean · ng•hr/mL
AUClast for Fraction of Ertugliflozin Unbound in Plasma (AUClast,u)
ng•hr/mLErtugliflozin 15 mg (Moderate Hepatic Impairment)Ertugliflozin 15 mg (Normal Hepatic Function)
AUClast for Fraction of Ertugliflozin Unbound in Plasma (AUClast,u)52.47 ± 4454.77 ± 15
Statistical analysis
  • Ertugliflozin 15 mg (Moderate Hepatic Impairment) vs Ertugliflozin 15 mg (Normal Hepatic Function) · Ratio (test/reference) of adjusted means: 95.81 · 90% CI 72.40 to 126.79ANOVA model with hepatic function group as a fixed effect, ratios (and 90% confidence intervals \[CIs\]) were expressed as percentages, Moderate Hepatic Impairment (Test), Normal Hepatic Function (Reference).
SecondaryAUCinf for Fraction of Ertugliflozin Unbound in Plasma (AUCinf,u)

Area under the plasma concentration-time profile from time zero extrapolated to infinite time for unbound drug (ertugliflozin only) (AUCinf, u).

Time frame:
Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours
Reported as:
Geometric mean · ng•hr/mL
AUCinf for Fraction of Ertugliflozin Unbound in Plasma (AUCinf,u)
ng•hr/mLErtugliflozin 15 mg (Moderate Hepatic Impairment)Ertugliflozin 15 mg (Normal Hepatic Function)
AUCinf for Fraction of Ertugliflozin Unbound in Plasma (AUCinf,u)53.14 ± 4455.40 ± 16
Statistical analysis
  • Ertugliflozin 15 mg (Moderate Hepatic Impairment) vs Ertugliflozin 15 mg (Normal Hepatic Function) · Ratio (test/reference) of adjusted means: 95.92 · 90% CI 72.46 to 126.97ANOVA model with hepatic function group as a fixed effect, ratios (and 90% confidence intervals \[CIs\]) were expressed as percentages, Moderate Hepatic Impairment (Test), Normal Hepatic Function (Reference).
SecondaryMaximum Plasma Concentration (Cmax) of Ertugliflozin

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.

Time frame:
Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of Ertugliflozin
ng/mLErtugliflozin 15 mg (Moderate Hepatic Impairment)Ertugliflozin 15 mg (Normal Hepatic Function)
Maximum Plasma Concentration (Cmax) of Ertugliflozin251.1 ± 27319.0 ± 11
Statistical analysis
  • Ertugliflozin 15 mg (Moderate Hepatic Impairment) vs Ertugliflozin 15 mg (Normal Hepatic Function) · Ratio (test/reference) of adjusted means: 78.70 · 90% CI 65.74 to 94.23ANOVA model with hepatic function group as a fixed effect, ratios (and 90% confidence intervals \[CIs\]) were expressed as percentages, Moderate Hepatic Impairment (Test), Normal Hepatic Function (Reference).
SecondaryCmax for Fraction of Ertugliflozin Unbound in Plasma (Cmax,u)

Maximum plasma concentration for unbound drug (ertugliflozin only).

Time frame:
Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours
Reported as:
Geometric mean · ng/mL
Cmax for Fraction of Ertugliflozin Unbound in Plasma (Cmax,u)
ng/mLErtugliflozin 15 mg (Moderate Hepatic Impairment)Ertugliflozin 15 mg (Normal Hepatic Function)
Cmax for Fraction of Ertugliflozin Unbound in Plasma (Cmax,u)9.336 ± 3010.79 ± 15
Statistical analysis
  • Ertugliflozin 15 mg (Moderate Hepatic Impairment) vs Ertugliflozin 15 mg (Normal Hepatic Function) · Ratio (test/reference) of adjusted means: 86.52 · 90% CI 70.49 to 106.20ANOVA model with hepatic function group as a fixed effect, ratios (and 90% confidence intervals \[CIs\]) were expressed as percentages, Moderate Hepatic Impairment (Test), Normal Hepatic Function (Reference).
SecondaryNumber of Participants Who Experienced an Adverse Event

An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 19 days
Reported as:
Number · Participants
Number of Participants Who Experienced an Adverse Event
ParticipantsErtugliflozin 15 mg (Moderate Hepatic Impairment)Ertugliflozin 15 mg (Normal Hepatic Function)
Number of Participants Who Experienced an Adverse Event23

Adverse events

Collected over Up to Day 19. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ertugliflozin 15 mg (Moderate Hepatic Impairment)—0/8 (0%)2/8 (25%)
Ertugliflozin 15 mg (Normal Hepatic Function)—0/8 (0%)3/8 (37.5%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventErtugliflozin 15 mg (Moderate Hepatic Impairment)Ertugliflozin 15 mg (Normal Hepatic Function)
TachycardiaCardiac disorders1/80/8
NauseaGastrointestinal disorders0/81/8
FuruncleInfections and infestations0/81/8
Decreased appetiteMetabolism and nutrition disorders1/80/8
ArthralgiaMusculoskeletal and connective tissue disorders0/81/8
Back painMusculoskeletal and connective tissue disorders0/81/8
MyalgiaMusculoskeletal and connective tissue disorders0/81/8
DizzinessNervous system disorders0/81/8
HeadacheNervous system disorders1/80/8
ParaesthesiaNervous system disorders0/81/8

Baseline characteristics

The PK concentration population was defined as all participants treated who had at least 1 concentration measurement. Based on evaluation of the PK data from participants with moderate hepatic impairment and matched healthy volunteers, Part 2 of the study was not conducted and participants with mild hepatic impairment were not enrolled.

Age, Continuous
Age, Continuous(Years)Ertugliflozin 15 mg (Moderate Hepatic Impairment)Ertugliflozin 15 mg (Normal Hepatic Function)Total
Mean55.1 ± 3.455.5 ± 3.055.3 (49 to 60)
Sex: Female, Male
Sex: Female, Male(Participants)Ertugliflozin 15 mg (Moderate Hepatic Impairment)Ertugliflozin 15 mg (Normal Hepatic Function)Total
Female448
Male448
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Marshall JC, Liang Y, Sahasrabudhe V, Tensfeldt T, Fediuk DJ, Zhou S, Krishna R, Dawra VK, Wood LS, Sweeney K. Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure. J Clin Pharmacol. 2021 Sep;61(9):1220-1231. doi: 10.1002/jcph.1866. Epub 2021 Jun 19. PubMed 33813736 ↗
  • Sahasrabudhe V, Terra SG, Hickman A, Saur D, Raje S, Shi H, Matschke K, Zhou S, Cutler DL. Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment. Clin Ther. 2018 Oct;40(10):1701-1710. doi: 10.1016/j.clinthera.2018.06.015. Epub 2018 Sep 14. PubMed 30224193 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Jan 2015, 3 months.

Results were first posted in Aug 2018, 3 years 6 months after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 3 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2014
First posted
Apr 16, 2014
StartActual
Sep 19, 2014
Primary completionActual
Jan 10, 2015
CompletionActual
Jan 19, 2015
Results first posted
Aug 3, 2018
Last update
Aug 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02115347
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Apr 16, 2014
Start date
Sep 19, 2014
Primary completion
Jan 10, 2015
Completion
Jan 19, 2015
Results posted
Aug 3, 2018
Last update
Aug 20, 2018

Study contacts

Medical Director
study director · Merck/Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertugliflozin

Start the discussion